Market accessOfficial

MHRA publishes November 2026 list of terminated and cancelled UK manufacturing and wholesale licences

🇬🇧 MHRA · Tue 10 Nov 2026

The agency has replaced its October list with a November 2026 version naming UK companies whose licences to manufacture or wholesale medicines have been terminated, cancelled or revoked.

The Medicines and Healthcare products Regulatory Agency (MHRA) updated its notice on terminated and cancelled manufacturing and wholesale dealer licences on 10 November 2026. The page now carries the November 2026 edition of the list, which replaces the October 2026 file.

The list is published as a CSV file of about 17 KB. It covers UK companies that no longer hold a licence to manufacture or wholesale medicines. The page title and file name also refer to revoked licences, although the short description mentions only terminated and cancelled ones.

The MHRA draws a distinction between the two main routes. Termination happens at the request of the licence holder, for example when a business decides it no longer wants to carry out an activity that requires a licence, authorisation or registration. Cancellation occurs when the MHRA itself decides to cancel the licence, authorisation or registration.

The notice was first published on 4 February 2015 and has since been refreshed on a roughly monthly basis. The update history shows a new list file in each month of 2026 to date, from February through November, along with a December 2025 file added in the preceding winter. The source text does not name any individual companies or give the number of entries in the November file.

What it means for your team

  • Quality assurance teams should compare the November 2026 file against their approved supplier, contract manufacturer and wholesale distributor lists, as dealing with an unlicensed party could create compliance and supply risks.
  • Because the MHRA updates the list monthly, a periodic check built into supplier-qualification routines would pick up new entries.
  • Check whether any listed company was terminated at its own request or cancelled by the MHRA, since the MHRA treats the two differently. Contract partners that appear should be followed up directly.
  • Pharmacovigilance and supply-chain teams should confirm that no affected party plays a role in distribution or batch release for their products.

Official source: MHRA ↗

Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.

More Market access All →